Thanks hottod Do you have any numbers on the incidence of...

First 5 Last

Share
Profile

Follow
mjc159

1,534 Posts.

156

23/03/15

15:58

Post #: 14963172
Share

Originally posted by hottod ↑

If nothing else, the Biogen story shows that the market loves therapies with successful trials in neurological conditions where there is a large market with unmet need.

Alzheimer’s is perhaps the most obvious condition in this category as it taps into the aging Baby Boomer market. There are estimated to be more than 5 million Americans with Alzheimer’s, with the annual incidence in the US estimated to be approximately 470,000.

But there are also other neurological conditions with large markets of unmet need.

Traumatic brain injury is one. In the United States the estimated annual incidence of TBI (a condition with no current treatment) is 1.7 million. Neuren’s Phase 2 results of NNZ-2566 in both mild and moderate to severe TBI should be known by later this year. With Neuren’s current shareprice at .10, the market doesn’t seem to be anticipating trial success. But what if the trials do demonstrate efficacy? What if the drug demonstrates not only efficacy, but also a better safety profile than Biogen’s drug?

It’s also worth remembering Neuren’s second drug, NNZ-2591, which is currently being prepared for IND submission. It has already demonstrated efficacy in pre-clinical models of stroke. The estimated annual incidence of stroke in the US is 800,000 – higher than Alzheimer’s. Finally, it shouldn't be forgotten that the patent for NNZ-2591, issued last year with respect to “improvement of cognitive performance in impaired animals”, also makes claim for treatment of Alzheimer’s Disease, Dementia, Parkinson’s Disease and age-related memory loss (along with other conditions).

Expand

Thanks hottod

Do you have any numbers on the incidence of age-related memory loss. From personal experience, it starts to kick-in around 40.
"Where did I put my car keys again?"

NEU Price at posting: 10.0¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

PL3

Patagonia looks to raise $2.15M for South American exploration and development

There are more pages in this discussion • 2 more messages in this thread...

First 5 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $19.50		Change -0.490(2.45%)		Mkt cap ! $2.492B

Open	High	Low	Value	Volume
$20.10	$20.10	$19.30	$8.547M	438.7K

Buyers (Bids)

No.	Vol.	Price($)
1	100	$19.48

Sellers (Offers)

Price($)	Vol.	No.
$19.50	3021	2

View Market Depth

No.	Vol.	Price($)
1	100	19.480
1	200	19.410
1	117	19.400
2	568	19.390
1	2876	19.370

Price($)	Vol.	No.
19.500	2753	1
19.520	1000	1
19.530	1144	2
19.550	2123	1
19.560	1000	1

Last trade - 16.10pm 09/07/2024 (20 minute delay)

NEU (ASX) Chart

Thanks hottod Do you have any numbers on the incidence of...

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks hottod Do you have any numbers on the incidence of...

Top Stories

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News